nodes	percent_of_prediction	percent_of_DWPC	metapath
Gefitinib—lung cancer—bone cancer	0.438	1	CtDrD
Gefitinib—CHEK2—bone cancer	0.248	0.647	CbGaD
Gefitinib—EGFR—bone cancer	0.0993	0.259	CbGaD
Gefitinib—CYP3A4—bone cancer	0.0363	0.0944	CbGaD
Gefitinib—ABCG2—Carboplatin—bone cancer	0.0166	0.212	CbGbCtD
Gefitinib—ABCG2—Cisplatin—bone cancer	0.0142	0.181	CbGbCtD
Gefitinib—ABCG2—Doxorubicin—bone cancer	0.00952	0.121	CbGbCtD
Gefitinib—ABCG2—Methotrexate—bone cancer	0.00922	0.118	CbGbCtD
Gefitinib—ALB—Methotrexate—bone cancer	0.00635	0.0811	CbGbCtD
Gefitinib—CYP2C9—Cisplatin—bone cancer	0.00528	0.0674	CbGbCtD
Gefitinib—ABCB1—Cisplatin—bone cancer	0.00512	0.0654	CbGbCtD
Gefitinib—ABCB1—Doxorubicin—bone cancer	0.00343	0.0438	CbGbCtD
Gefitinib—ABCB1—Methotrexate—bone cancer	0.00332	0.0424	CbGbCtD
Gefitinib—CYP2D6—Doxorubicin—bone cancer	0.00323	0.0413	CbGbCtD
Gefitinib—CYP3A4—Doxorubicin—bone cancer	0.00206	0.0262	CbGbCtD
Gefitinib—Lapatinib—EGFR—bone cancer	0.000601	0.177	CrCbGaD
Gefitinib—CHEK2—Doxorubicin—Epirubicin—bone cancer	0.000563	0.519	CbGdCrCtD
Gefitinib—Erlotinib—NR1I2—bone cancer	0.000555	0.163	CrCbGaD
Gefitinib—CHEK2—Epirubicin—Doxorubicin—bone cancer	0.000521	0.481	CbGdCrCtD
Gefitinib—Bosutinib—CHEK2—bone cancer	0.000464	0.137	CrCbGaD
Gefitinib—Afatinib—EGFR—bone cancer	0.000426	0.125	CrCbGaD
Gefitinib—Erlotinib—EGFR—bone cancer	0.000301	0.0885	CrCbGaD
Gefitinib—Lapatinib—CYP3A4—bone cancer	0.000219	0.0646	CrCbGaD
Gefitinib—Pleural effusion—Epirubicin—bone cancer	0.000212	0.00498	CcSEcCtD
Gefitinib—Amblyopia—Epirubicin—bone cancer	0.00021	0.00493	CcSEcCtD
Gefitinib—Hypokalaemia—Cisplatin—bone cancer	0.000209	0.0049	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Cisplatin—bone cancer	0.000207	0.00485	CcSEcCtD
Gefitinib—Rash pustular—Epirubicin—bone cancer	0.000204	0.00478	CcSEcCtD
Gefitinib—Haemoptysis—Doxorubicin—bone cancer	0.000203	0.00476	CcSEcCtD
Gefitinib—Vandetanib—EGFR—bone cancer	0.000198	0.0583	CrCbGaD
Gefitinib—Proteinuria—Methotrexate—bone cancer	0.000197	0.00463	CcSEcCtD
Gefitinib—Pleural effusion—Doxorubicin—bone cancer	0.000196	0.0046	CcSEcCtD
Gefitinib—Protein urine present—Methotrexate—bone cancer	0.000195	0.00457	CcSEcCtD
Gefitinib—Amblyopia—Doxorubicin—bone cancer	0.000195	0.00457	CcSEcCtD
Gefitinib—Pancreatitis—Cisplatin—bone cancer	0.000194	0.00456	CcSEcCtD
Gefitinib—Rash pustular—Doxorubicin—bone cancer	0.000188	0.00442	CcSEcCtD
Gefitinib—Bosutinib—EGFR—bone cancer	0.000185	0.0546	CrCbGaD
Gefitinib—Ulcer—Methotrexate—bone cancer	0.000183	0.0043	CcSEcCtD
Gefitinib—Respiratory failure—Methotrexate—bone cancer	0.000177	0.00415	CcSEcCtD
Gefitinib—Stomatitis—Cisplatin—bone cancer	0.000172	0.00405	CcSEcCtD
Gefitinib—Conjunctivitis—Cisplatin—bone cancer	0.000172	0.00403	CcSEcCtD
Gefitinib—Ulcer—Epirubicin—bone cancer	0.000172	0.00403	CcSEcCtD
Gefitinib—Cystitis noninfective—Methotrexate—bone cancer	0.000169	0.00398	CcSEcCtD
Gefitinib—Melaena—Methotrexate—bone cancer	0.000169	0.00398	CcSEcCtD
Gefitinib—Cystitis—Methotrexate—bone cancer	0.000168	0.00393	CcSEcCtD
Gefitinib—Hepatobiliary disease—Cisplatin—bone cancer	0.000167	0.00393	CcSEcCtD
Gefitinib—Ulcer—Doxorubicin—bone cancer	0.000159	0.00373	CcSEcCtD
Gefitinib—Cystitis noninfective—Epirubicin—bone cancer	0.000159	0.00372	CcSEcCtD
Gefitinib—Melaena—Epirubicin—bone cancer	0.000159	0.00372	CcSEcCtD
Gefitinib—Bladder pain—Methotrexate—bone cancer	0.000157	0.00368	CcSEcCtD
Gefitinib—Mouth ulceration—Methotrexate—bone cancer	0.000157	0.00368	CcSEcCtD
Gefitinib—Urinary tract disorder—Cisplatin—bone cancer	0.000157	0.00368	CcSEcCtD
Gefitinib—Cystitis—Epirubicin—bone cancer	0.000157	0.00368	CcSEcCtD
Gefitinib—Urethral disorder—Cisplatin—bone cancer	0.000156	0.00365	CcSEcCtD
Gefitinib—Dry eye—Epirubicin—bone cancer	0.00015	0.00352	CcSEcCtD
Gefitinib—Eye disorder—Cisplatin—bone cancer	0.000148	0.00348	CcSEcCtD
Gefitinib—Cardiac disorder—Cisplatin—bone cancer	0.000147	0.00346	CcSEcCtD
Gefitinib—Bladder pain—Epirubicin—bone cancer	0.000147	0.00345	CcSEcCtD
Gefitinib—Mouth ulceration—Epirubicin—bone cancer	0.000147	0.00345	CcSEcCtD
Gefitinib—Cystitis noninfective—Doxorubicin—bone cancer	0.000147	0.00344	CcSEcCtD
Gefitinib—Melaena—Doxorubicin—bone cancer	0.000147	0.00344	CcSEcCtD
Gefitinib—Thrombophlebitis—Methotrexate—bone cancer	0.000145	0.00341	CcSEcCtD
Gefitinib—Cystitis—Doxorubicin—bone cancer	0.000145	0.0034	CcSEcCtD
Gefitinib—Mediastinal disorder—Cisplatin—bone cancer	0.000143	0.00336	CcSEcCtD
Gefitinib—Arrhythmia—Cisplatin—bone cancer	0.000142	0.00333	CcSEcCtD
Gefitinib—Alopecia—Cisplatin—bone cancer	0.00014	0.00329	CcSEcCtD
Gefitinib—Hepatic failure—Methotrexate—bone cancer	0.00014	0.00329	CcSEcCtD
Gefitinib—Dry eye—Doxorubicin—bone cancer	0.000139	0.00326	CcSEcCtD
Gefitinib—ORM1—vertebral column—bone cancer	0.000138	0.125	CbGeAlD
Gefitinib—Malnutrition—Cisplatin—bone cancer	0.000138	0.00324	CcSEcCtD
Gefitinib—Thrombophlebitis—Epirubicin—bone cancer	0.000136	0.0032	CcSEcCtD
Gefitinib—Bladder pain—Doxorubicin—bone cancer	0.000136	0.00319	CcSEcCtD
Gefitinib—Mouth ulceration—Doxorubicin—bone cancer	0.000136	0.00319	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Methotrexate—bone cancer	0.000133	0.00313	CcSEcCtD
Gefitinib—Hepatic failure—Epirubicin—bone cancer	0.000131	0.00308	CcSEcCtD
Gefitinib—Eye pain—Epirubicin—bone cancer	0.000131	0.00306	CcSEcCtD
Gefitinib—Anaemia—Cisplatin—bone cancer	0.000128	0.003	CcSEcCtD
Gefitinib—Thrombophlebitis—Doxorubicin—bone cancer	0.000126	0.00296	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Epirubicin—bone cancer	0.000125	0.00293	CcSEcCtD
Gefitinib—Malaise—Cisplatin—bone cancer	0.000125	0.00293	CcSEcCtD
Gefitinib—Dermatitis bullous—Epirubicin—bone cancer	0.000123	0.00289	CcSEcCtD
Gefitinib—Hepatic failure—Doxorubicin—bone cancer	0.000121	0.00285	CcSEcCtD
Gefitinib—Eye pain—Doxorubicin—bone cancer	0.000121	0.00283	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000117	0.00274	CcSEcCtD
Gefitinib—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000116	0.00271	CcSEcCtD
Gefitinib—Dermatitis bullous—Doxorubicin—bone cancer	0.000114	0.00268	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000113	0.00266	CcSEcCtD
Gefitinib—Infection—Cisplatin—bone cancer	0.000112	0.00263	CcSEcCtD
Gefitinib—Nervous system disorder—Cisplatin—bone cancer	0.000111	0.0026	CcSEcCtD
Gefitinib—Thrombocytopenia—Cisplatin—bone cancer	0.00011	0.00259	CcSEcCtD
Gefitinib—Erlotinib—CYP3A4—bone cancer	0.00011	0.0323	CrCbGaD
Gefitinib—Dehydration—Epirubicin—bone cancer	0.00011	0.00257	CcSEcCtD
Gefitinib—Skin disorder—Cisplatin—bone cancer	0.00011	0.00257	CcSEcCtD
Gefitinib—Dry skin—Epirubicin—bone cancer	0.000108	0.00254	CcSEcCtD
Gefitinib—Anorexia—Cisplatin—bone cancer	0.000108	0.00252	CcSEcCtD
Gefitinib—Hypokalaemia—Epirubicin—bone cancer	0.000107	0.00252	CcSEcCtD
Gefitinib—Pancreatitis—Methotrexate—bone cancer	0.000107	0.0025	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Epirubicin—bone cancer	0.000106	0.00249	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000106	0.00249	CcSEcCtD
Gefitinib—Hypotension—Cisplatin—bone cancer	0.000105	0.00247	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Epirubicin—bone cancer	0.000104	0.00244	CcSEcCtD
Gefitinib—Cisapride—CYP3A4—bone cancer	0.000104	0.0305	CrCbGaD
Gefitinib—Dehydration—Doxorubicin—bone cancer	0.000101	0.00238	CcSEcCtD
Gefitinib—Dyspnoea—Cisplatin—bone cancer	0.000101	0.00236	CcSEcCtD
Gefitinib—Dry skin—Doxorubicin—bone cancer	0.0001	0.00235	CcSEcCtD
Gefitinib—Pancreatitis—Epirubicin—bone cancer	9.99e-05	0.00234	CcSEcCtD
Gefitinib—Hypokalaemia—Doxorubicin—bone cancer	9.93e-05	0.00233	CcSEcCtD
Gefitinib—Aspartate aminotransferase increased—Doxorubicin—bone cancer	9.82e-05	0.0023	CcSEcCtD
Gefitinib—Toxic epidermal necrolysis—Doxorubicin—bone cancer	9.82e-05	0.0023	CcSEcCtD
Gefitinib—Decreased appetite—Cisplatin—bone cancer	9.81e-05	0.0023	CcSEcCtD
Gefitinib—Pneumonia—Methotrexate—bone cancer	9.76e-05	0.00229	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Cisplatin—bone cancer	9.74e-05	0.00229	CcSEcCtD
Gefitinib—Infestation NOS—Methotrexate—bone cancer	9.71e-05	0.00228	CcSEcCtD
Gefitinib—Infestation—Methotrexate—bone cancer	9.71e-05	0.00228	CcSEcCtD
Gefitinib—Pain—Cisplatin—bone cancer	9.65e-05	0.00226	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Methotrexate—bone cancer	9.62e-05	0.00226	CcSEcCtD
Gefitinib—Alanine aminotransferase increased—Doxorubicin—bone cancer	9.62e-05	0.00226	CcSEcCtD
Gefitinib—Iloperidone—CYP3A4—bone cancer	9.55e-05	0.0281	CrCbGaD
Gefitinib—Stomatitis—Methotrexate—bone cancer	9.46e-05	0.00222	CcSEcCtD
Gefitinib—Conjunctivitis—Methotrexate—bone cancer	9.43e-05	0.00221	CcSEcCtD
Gefitinib—Haematuria—Methotrexate—bone cancer	9.25e-05	0.00217	CcSEcCtD
Gefitinib—Pancreatitis—Doxorubicin—bone cancer	9.24e-05	0.00217	CcSEcCtD
Gefitinib—Weight decreased—Epirubicin—bone cancer	9.22e-05	0.00216	CcSEcCtD
Gefitinib—Hepatobiliary disease—Methotrexate—bone cancer	9.18e-05	0.00215	CcSEcCtD
Gefitinib—Epistaxis—Methotrexate—bone cancer	9.15e-05	0.00215	CcSEcCtD
Gefitinib—Pneumonia—Epirubicin—bone cancer	9.14e-05	0.00214	CcSEcCtD
Gefitinib—Infestation—Epirubicin—bone cancer	9.08e-05	0.00213	CcSEcCtD
Gefitinib—Infestation NOS—Epirubicin—bone cancer	9.08e-05	0.00213	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Epirubicin—bone cancer	9.01e-05	0.00211	CcSEcCtD
Gefitinib—Body temperature increased—Cisplatin—bone cancer	8.92e-05	0.00209	CcSEcCtD
Gefitinib—Stomatitis—Epirubicin—bone cancer	8.85e-05	0.00208	CcSEcCtD
Gefitinib—Conjunctivitis—Epirubicin—bone cancer	8.83e-05	0.00207	CcSEcCtD
Gefitinib—Haemoglobin—Methotrexate—bone cancer	8.76e-05	0.00206	CcSEcCtD
Gefitinib—Haemorrhage—Methotrexate—bone cancer	8.71e-05	0.00204	CcSEcCtD
Gefitinib—Hepatitis—Methotrexate—bone cancer	8.71e-05	0.00204	CcSEcCtD
Gefitinib—Haematuria—Epirubicin—bone cancer	8.66e-05	0.00203	CcSEcCtD
Gefitinib—Urinary tract disorder—Methotrexate—bone cancer	8.6e-05	0.00202	CcSEcCtD
Gefitinib—Hepatobiliary disease—Epirubicin—bone cancer	8.59e-05	0.00202	CcSEcCtD
Gefitinib—Epistaxis—Epirubicin—bone cancer	8.57e-05	0.00201	CcSEcCtD
Gefitinib—Urethral disorder—Methotrexate—bone cancer	8.54e-05	0.002	CcSEcCtD
Gefitinib—Weight decreased—Doxorubicin—bone cancer	8.53e-05	0.002	CcSEcCtD
Gefitinib—Pneumonia—Doxorubicin—bone cancer	8.45e-05	0.00198	CcSEcCtD
Gefitinib—Infestation NOS—Doxorubicin—bone cancer	8.4e-05	0.00197	CcSEcCtD
Gefitinib—Infestation—Doxorubicin—bone cancer	8.4e-05	0.00197	CcSEcCtD
Gefitinib—Stevens-Johnson syndrome—Doxorubicin—bone cancer	8.33e-05	0.00196	CcSEcCtD
Gefitinib—Hypersensitivity—Cisplatin—bone cancer	8.31e-05	0.00195	CcSEcCtD
Gefitinib—Erythema multiforme—Methotrexate—bone cancer	8.24e-05	0.00193	CcSEcCtD
Gefitinib—Haemoglobin—Epirubicin—bone cancer	8.2e-05	0.00192	CcSEcCtD
Gefitinib—Stomatitis—Doxorubicin—bone cancer	8.19e-05	0.00192	CcSEcCtD
Gefitinib—Conjunctivitis—Doxorubicin—bone cancer	8.17e-05	0.00192	CcSEcCtD
Gefitinib—Hepatitis—Epirubicin—bone cancer	8.15e-05	0.00191	CcSEcCtD
Gefitinib—Haemorrhage—Epirubicin—bone cancer	8.15e-05	0.00191	CcSEcCtD
Gefitinib—Eye disorder—Methotrexate—bone cancer	8.14e-05	0.00191	CcSEcCtD
Gefitinib—Asthenia—Cisplatin—bone cancer	8.09e-05	0.0019	CcSEcCtD
Gefitinib—Cardiac disorder—Methotrexate—bone cancer	8.09e-05	0.0019	CcSEcCtD
Gefitinib—Urinary tract disorder—Epirubicin—bone cancer	8.05e-05	0.00189	CcSEcCtD
Gefitinib—Oedema peripheral—Epirubicin—bone cancer	8.03e-05	0.00189	CcSEcCtD
Gefitinib—Haematuria—Doxorubicin—bone cancer	8.01e-05	0.00188	CcSEcCtD
Gefitinib—Urethral disorder—Epirubicin—bone cancer	7.99e-05	0.00188	CcSEcCtD
Gefitinib—Hepatobiliary disease—Doxorubicin—bone cancer	7.95e-05	0.00187	CcSEcCtD
Gefitinib—Epistaxis—Doxorubicin—bone cancer	7.93e-05	0.00186	CcSEcCtD
Gefitinib—Angiopathy—Methotrexate—bone cancer	7.91e-05	0.00186	CcSEcCtD
Gefitinib—Mediastinal disorder—Methotrexate—bone cancer	7.85e-05	0.00184	CcSEcCtD
Gefitinib—Diarrhoea—Cisplatin—bone cancer	7.72e-05	0.00181	CcSEcCtD
Gefitinib—Erythema multiforme—Epirubicin—bone cancer	7.71e-05	0.00181	CcSEcCtD
Gefitinib—Alopecia—Methotrexate—bone cancer	7.7e-05	0.00181	CcSEcCtD
Gefitinib—Eye disorder—Epirubicin—bone cancer	7.62e-05	0.00179	CcSEcCtD
Gefitinib—Malnutrition—Methotrexate—bone cancer	7.58e-05	0.00178	CcSEcCtD
Gefitinib—Haemoglobin—Doxorubicin—bone cancer	7.58e-05	0.00178	CcSEcCtD
Gefitinib—Cardiac disorder—Epirubicin—bone cancer	7.57e-05	0.00178	CcSEcCtD
Gefitinib—Haemorrhage—Doxorubicin—bone cancer	7.54e-05	0.00177	CcSEcCtD
Gefitinib—Hepatitis—Doxorubicin—bone cancer	7.54e-05	0.00177	CcSEcCtD
Gefitinib—Urinary tract disorder—Doxorubicin—bone cancer	7.45e-05	0.00175	CcSEcCtD
Gefitinib—Oedema peripheral—Doxorubicin—bone cancer	7.43e-05	0.00174	CcSEcCtD
Gefitinib—Angiopathy—Epirubicin—bone cancer	7.4e-05	0.00174	CcSEcCtD
Gefitinib—Urethral disorder—Doxorubicin—bone cancer	7.4e-05	0.00174	CcSEcCtD
Gefitinib—Mediastinal disorder—Epirubicin—bone cancer	7.35e-05	0.00172	CcSEcCtD
Gefitinib—Arrhythmia—Epirubicin—bone cancer	7.28e-05	0.00171	CcSEcCtD
Gefitinib—Vandetanib—CYP3A4—bone cancer	7.24e-05	0.0213	CrCbGaD
Gefitinib—Alopecia—Epirubicin—bone cancer	7.21e-05	0.00169	CcSEcCtD
Gefitinib—Vomiting—Cisplatin—bone cancer	7.17e-05	0.00168	CcSEcCtD
Gefitinib—Erythema multiforme—Doxorubicin—bone cancer	7.13e-05	0.00167	CcSEcCtD
Gefitinib—Rash—Cisplatin—bone cancer	7.11e-05	0.00167	CcSEcCtD
Gefitinib—Dermatitis—Cisplatin—bone cancer	7.11e-05	0.00167	CcSEcCtD
Gefitinib—Malnutrition—Epirubicin—bone cancer	7.1e-05	0.00167	CcSEcCtD
Gefitinib—Eye disorder—Doxorubicin—bone cancer	7.05e-05	0.00165	CcSEcCtD
Gefitinib—Anaemia—Methotrexate—bone cancer	7.01e-05	0.00165	CcSEcCtD
Gefitinib—Cardiac disorder—Doxorubicin—bone cancer	7e-05	0.00164	CcSEcCtD
Gefitinib—Angiopathy—Doxorubicin—bone cancer	6.85e-05	0.00161	CcSEcCtD
Gefitinib—Malaise—Methotrexate—bone cancer	6.84e-05	0.00161	CcSEcCtD
Gefitinib—Mediastinal disorder—Doxorubicin—bone cancer	6.8e-05	0.0016	CcSEcCtD
Gefitinib—Bosutinib—CYP3A4—bone cancer	6.77e-05	0.0199	CrCbGaD
Gefitinib—Arrhythmia—Doxorubicin—bone cancer	6.74e-05	0.00158	CcSEcCtD
Gefitinib—SBK1—tendon—bone cancer	6.7e-05	0.0605	CbGeAlD
Gefitinib—Nausea—Cisplatin—bone cancer	6.7e-05	0.00157	CcSEcCtD
Gefitinib—Alopecia—Doxorubicin—bone cancer	6.67e-05	0.00156	CcSEcCtD
Gefitinib—Cough—Methotrexate—bone cancer	6.62e-05	0.00155	CcSEcCtD
Gefitinib—Malnutrition—Doxorubicin—bone cancer	6.57e-05	0.00154	CcSEcCtD
Gefitinib—Anaemia—Epirubicin—bone cancer	6.56e-05	0.00154	CcSEcCtD
Gefitinib—SBK1—spinal cord—bone cancer	6.47e-05	0.0583	CbGeAlD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	6.41e-05	0.0015	CcSEcCtD
Gefitinib—Malaise—Epirubicin—bone cancer	6.4e-05	0.0015	CcSEcCtD
Gefitinib—Cough—Epirubicin—bone cancer	6.19e-05	0.00145	CcSEcCtD
Gefitinib—Infection—Methotrexate—bone cancer	6.15e-05	0.00144	CcSEcCtD
Gefitinib—Nervous system disorder—Methotrexate—bone cancer	6.07e-05	0.00142	CcSEcCtD
Gefitinib—Anaemia—Doxorubicin—bone cancer	6.07e-05	0.00142	CcSEcCtD
Gefitinib—Thrombocytopenia—Methotrexate—bone cancer	6.06e-05	0.00142	CcSEcCtD
Gefitinib—Skin disorder—Methotrexate—bone cancer	6.01e-05	0.00141	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	6e-05	0.00141	CcSEcCtD
Gefitinib—Malaise—Doxorubicin—bone cancer	5.92e-05	0.00139	CcSEcCtD
Gefitinib—Dry mouth—Epirubicin—bone cancer	5.91e-05	0.00139	CcSEcCtD
Gefitinib—Anorexia—Methotrexate—bone cancer	5.9e-05	0.00138	CcSEcCtD
Gefitinib—CHEK2—tendon—bone cancer	5.84e-05	0.0527	CbGeAlD
Gefitinib—Hypotension—Methotrexate—bone cancer	5.78e-05	0.00136	CcSEcCtD
Gefitinib—Infection—Epirubicin—bone cancer	5.76e-05	0.00135	CcSEcCtD
Gefitinib—Cough—Doxorubicin—bone cancer	5.73e-05	0.00134	CcSEcCtD
Gefitinib—Shock—Epirubicin—bone cancer	5.7e-05	0.00134	CcSEcCtD
Gefitinib—Nervous system disorder—Epirubicin—bone cancer	5.68e-05	0.00133	CcSEcCtD
Gefitinib—Thrombocytopenia—Epirubicin—bone cancer	5.67e-05	0.00133	CcSEcCtD
Gefitinib—CHEK2—bone marrow—bone cancer	5.66e-05	0.051	CbGeAlD
Gefitinib—Skin disorder—Epirubicin—bone cancer	5.63e-05	0.00132	CcSEcCtD
Gefitinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	5.55e-05	0.0013	CcSEcCtD
Gefitinib—Anorexia—Epirubicin—bone cancer	5.52e-05	0.0013	CcSEcCtD
Gefitinib—Dyspnoea—Methotrexate—bone cancer	5.52e-05	0.0013	CcSEcCtD
Gefitinib—Dry mouth—Doxorubicin—bone cancer	5.47e-05	0.00128	CcSEcCtD
Gefitinib—Hypotension—Epirubicin—bone cancer	5.41e-05	0.00127	CcSEcCtD
Gefitinib—Decreased appetite—Methotrexate—bone cancer	5.38e-05	0.00126	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Methotrexate—bone cancer	5.34e-05	0.00125	CcSEcCtD
Gefitinib—Fatigue—Methotrexate—bone cancer	5.34e-05	0.00125	CcSEcCtD
Gefitinib—Infection—Doxorubicin—bone cancer	5.33e-05	0.00125	CcSEcCtD
Gefitinib—Pain—Methotrexate—bone cancer	5.29e-05	0.00124	CcSEcCtD
Gefitinib—Shock—Doxorubicin—bone cancer	5.27e-05	0.00124	CcSEcCtD
Gefitinib—Nervous system disorder—Doxorubicin—bone cancer	5.26e-05	0.00123	CcSEcCtD
Gefitinib—Thrombocytopenia—Doxorubicin—bone cancer	5.25e-05	0.00123	CcSEcCtD
Gefitinib—Skin disorder—Doxorubicin—bone cancer	5.21e-05	0.00122	CcSEcCtD
Gefitinib—ERBB3—connective tissue—bone cancer	5.2e-05	0.0469	CbGeAlD
Gefitinib—Dyspnoea—Epirubicin—bone cancer	5.16e-05	0.00121	CcSEcCtD
Gefitinib—Anorexia—Doxorubicin—bone cancer	5.11e-05	0.0012	CcSEcCtD
Gefitinib—Gastrointestinal pain—Methotrexate—bone cancer	5.06e-05	0.00119	CcSEcCtD
Gefitinib—Decreased appetite—Epirubicin—bone cancer	5.04e-05	0.00118	CcSEcCtD
Gefitinib—Hypotension—Doxorubicin—bone cancer	5.01e-05	0.00118	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Epirubicin—bone cancer	5e-05	0.00117	CcSEcCtD
Gefitinib—Fatigue—Epirubicin—bone cancer	4.99e-05	0.00117	CcSEcCtD
Gefitinib—Constipation—Epirubicin—bone cancer	4.95e-05	0.00116	CcSEcCtD
Gefitinib—Pain—Epirubicin—bone cancer	4.95e-05	0.00116	CcSEcCtD
Gefitinib—MKNK2—connective tissue—bone cancer	4.94e-05	0.0446	CbGeAlD
Gefitinib—Urticaria—Methotrexate—bone cancer	4.92e-05	0.00115	CcSEcCtD
Gefitinib—Body temperature increased—Methotrexate—bone cancer	4.89e-05	0.00115	CcSEcCtD
Gefitinib—Abdominal pain—Methotrexate—bone cancer	4.89e-05	0.00115	CcSEcCtD
Gefitinib—Dyspnoea—Doxorubicin—bone cancer	4.78e-05	0.00112	CcSEcCtD
Gefitinib—Gastrointestinal pain—Epirubicin—bone cancer	4.74e-05	0.00111	CcSEcCtD
Gefitinib—Decreased appetite—Doxorubicin—bone cancer	4.66e-05	0.00109	CcSEcCtD
Gefitinib—Gastrointestinal disorder—Doxorubicin—bone cancer	4.63e-05	0.00109	CcSEcCtD
Gefitinib—Fatigue—Doxorubicin—bone cancer	4.62e-05	0.00108	CcSEcCtD
Gefitinib—Urticaria—Epirubicin—bone cancer	4.6e-05	0.00108	CcSEcCtD
Gefitinib—Pain—Doxorubicin—bone cancer	4.58e-05	0.00108	CcSEcCtD
Gefitinib—Constipation—Doxorubicin—bone cancer	4.58e-05	0.00108	CcSEcCtD
Gefitinib—Body temperature increased—Epirubicin—bone cancer	4.58e-05	0.00107	CcSEcCtD
Gefitinib—Abdominal pain—Epirubicin—bone cancer	4.58e-05	0.00107	CcSEcCtD
Gefitinib—Hypersensitivity—Methotrexate—bone cancer	4.56e-05	0.00107	CcSEcCtD
Gefitinib—Asthenia—Methotrexate—bone cancer	4.44e-05	0.00104	CcSEcCtD
Gefitinib—Gastrointestinal pain—Doxorubicin—bone cancer	4.38e-05	0.00103	CcSEcCtD
Gefitinib—Pruritus—Methotrexate—bone cancer	4.38e-05	0.00103	CcSEcCtD
Gefitinib—Hypersensitivity—Epirubicin—bone cancer	4.27e-05	0.001	CcSEcCtD
Gefitinib—Urticaria—Doxorubicin—bone cancer	4.26e-05	0.000999	CcSEcCtD
Gefitinib—Abdominal pain—Doxorubicin—bone cancer	4.24e-05	0.000994	CcSEcCtD
Gefitinib—Body temperature increased—Doxorubicin—bone cancer	4.24e-05	0.000994	CcSEcCtD
Gefitinib—Diarrhoea—Methotrexate—bone cancer	4.24e-05	0.000994	CcSEcCtD
Gefitinib—Asthenia—Epirubicin—bone cancer	4.16e-05	0.000975	CcSEcCtD
Gefitinib—Pruritus—Epirubicin—bone cancer	4.1e-05	0.000962	CcSEcCtD
Gefitinib—Diarrhoea—Epirubicin—bone cancer	3.96e-05	0.00093	CcSEcCtD
Gefitinib—Hypersensitivity—Doxorubicin—bone cancer	3.95e-05	0.000927	CcSEcCtD
Gefitinib—Vomiting—Methotrexate—bone cancer	3.94e-05	0.000924	CcSEcCtD
Gefitinib—Rash—Methotrexate—bone cancer	3.9e-05	0.000916	CcSEcCtD
Gefitinib—Dermatitis—Methotrexate—bone cancer	3.9e-05	0.000915	CcSEcCtD
Gefitinib—Asthenia—Doxorubicin—bone cancer	3.85e-05	0.000903	CcSEcCtD
Gefitinib—Pruritus—Doxorubicin—bone cancer	3.79e-05	0.00089	CcSEcCtD
Gefitinib—CSNK1E—tendon—bone cancer	3.7e-05	0.0334	CbGeAlD
Gefitinib—Vomiting—Epirubicin—bone cancer	3.68e-05	0.000864	CcSEcCtD
Gefitinib—Nausea—Methotrexate—bone cancer	3.68e-05	0.000863	CcSEcCtD
Gefitinib—Diarrhoea—Doxorubicin—bone cancer	3.67e-05	0.000861	CcSEcCtD
Gefitinib—Rash—Epirubicin—bone cancer	3.65e-05	0.000857	CcSEcCtD
Gefitinib—Dermatitis—Epirubicin—bone cancer	3.65e-05	0.000856	CcSEcCtD
Gefitinib—IRAK4—tendon—bone cancer	3.64e-05	0.0329	CbGeAlD
Gefitinib—CSNK1E—spinal cord—bone cancer	3.57e-05	0.0322	CbGeAlD
Gefitinib—IRAK4—bone marrow—bone cancer	3.53e-05	0.0319	CbGeAlD
Gefitinib—IRAK4—spinal cord—bone cancer	3.52e-05	0.0317	CbGeAlD
Gefitinib—ERBB3—spinal cord—bone cancer	3.45e-05	0.0311	CbGeAlD
Gefitinib—Nausea—Epirubicin—bone cancer	3.44e-05	0.000808	CcSEcCtD
Gefitinib—Vomiting—Doxorubicin—bone cancer	3.41e-05	0.0008	CcSEcCtD
Gefitinib—IRAK1—tendon—bone cancer	3.4e-05	0.0307	CbGeAlD
Gefitinib—MKNK2—tendon—bone cancer	3.4e-05	0.0307	CbGeAlD
Gefitinib—Rash—Doxorubicin—bone cancer	3.38e-05	0.000793	CcSEcCtD
Gefitinib—Dermatitis—Doxorubicin—bone cancer	3.38e-05	0.000792	CcSEcCtD
Gefitinib—MKNK2—bone marrow—bone cancer	3.29e-05	0.0297	CbGeAlD
Gefitinib—IRAK1—bone marrow—bone cancer	3.29e-05	0.0297	CbGeAlD
Gefitinib—MKNK2—spinal cord—bone cancer	3.28e-05	0.0296	CbGeAlD
Gefitinib—MKNK1—bone marrow—bone cancer	3.25e-05	0.0293	CbGeAlD
Gefitinib—MKNK1—spinal cord—bone cancer	3.24e-05	0.0292	CbGeAlD
Gefitinib—Nausea—Doxorubicin—bone cancer	3.18e-05	0.000747	CcSEcCtD
Gefitinib—STK10—tendon—bone cancer	2.76e-05	0.0249	CbGeAlD
Gefitinib—STK10—bone marrow—bone cancer	2.68e-05	0.0241	CbGeAlD
Gefitinib—MAP2K5—tendon—bone cancer	2.47e-05	0.0223	CbGeAlD
Gefitinib—MAP2K5—spinal cord—bone cancer	2.38e-05	0.0215	CbGeAlD
Gefitinib—ORM1—bone marrow—bone cancer	1.94e-05	0.0175	CbGeAlD
Gefitinib—ORM1—spinal cord—bone cancer	1.93e-05	0.0174	CbGeAlD
Gefitinib—EGFR—Signaling by NGF—KIT—bone cancer	1.57e-05	0.000306	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	1.57e-05	0.000306	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	1.56e-05	0.000305	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—KIT—bone cancer	1.54e-05	0.000301	CbGpPWpGaD
Gefitinib—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.54e-05	0.0003	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NDUFA12—bone cancer	1.53e-05	0.000298	CbGpPWpGaD
Gefitinib—EPHA6—Developmental Biology—EGFR—bone cancer	1.52e-05	0.000297	CbGpPWpGaD
Gefitinib—ERBB3—Signaling by NGF—EGFR—bone cancer	1.52e-05	0.000296	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MET—bone cancer	1.51e-05	0.000294	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—GNA11—bone cancer	1.5e-05	0.000293	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TGFBR2—bone cancer	1.5e-05	0.000292	CbGpPWpGaD
Gefitinib—EGFR—Focal Adhesion—JUN—bone cancer	1.49e-05	0.000291	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	1.48e-05	0.000289	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—GRM1—bone cancer	1.48e-05	0.000288	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—BRAF—bone cancer	1.47e-05	0.000288	CbGpPWpGaD
Gefitinib—MKNK1—Disease—KIT—bone cancer	1.46e-05	0.000285	CbGpPWpGaD
Gefitinib—EGFR—Spinal Cord Injury—TP53—bone cancer	1.44e-05	0.000281	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—IGF1R—bone cancer	1.41e-05	0.000275	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—ATF1—bone cancer	1.39e-05	0.000272	CbGpPWpGaD
Gefitinib—ALB—Metabolism—NDUFA12—bone cancer	1.39e-05	0.000272	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—JUN—bone cancer	1.38e-05	0.000269	CbGpPWpGaD
Gefitinib—MKNK1—Disease—BRAF—bone cancer	1.37e-05	0.000268	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—ATF1—bone cancer	1.37e-05	0.000267	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IL3—bone cancer	1.36e-05	0.000266	CbGpPWpGaD
Gefitinib—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	1.35e-05	0.000263	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—NT5C3A—bone cancer	1.34e-05	0.000262	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—KIT—bone cancer	1.34e-05	0.000261	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—IL3—bone cancer	1.33e-05	0.000261	CbGpPWpGaD
Gefitinib—ALB—Folate Metabolism—TP53—bone cancer	1.32e-05	0.000258	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—SMO—bone cancer	1.3e-05	0.000253	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—NT5C3A—bone cancer	1.27e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Disease—TGFBR2—bone cancer	1.27e-05	0.000247	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—MDM2—bone cancer	1.26e-05	0.000247	CbGpPWpGaD
Gefitinib—IRAK1—Signaling by NGF—EGFR—bone cancer	1.26e-05	0.000246	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP2—bone cancer	1.26e-05	0.000246	CbGpPWpGaD
Gefitinib—EGFR—Direct p53 effectors—TP53—bone cancer	1.25e-05	0.000245	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NDUFA12—bone cancer	1.25e-05	0.000244	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—SMO—bone cancer	1.25e-05	0.000244	CbGpPWpGaD
Gefitinib—EGFR—Signaling by NGF—MDM2—bone cancer	1.23e-05	0.000241	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NDUFA12—bone cancer	1.22e-05	0.000238	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—MDM2—bone cancer	1.21e-05	0.000237	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—GNA11—bone cancer	1.19e-05	0.000232	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—SPARC—bone cancer	1.18e-05	0.000231	CbGpPWpGaD
Gefitinib—EGFR—Integrated Breast Cancer Pathway—TP53—bone cancer	1.18e-05	0.000231	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—SMO—bone cancer	1.18e-05	0.00023	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—KIT—bone cancer	1.17e-05	0.000229	CbGpPWpGaD
Gefitinib—CHEK2—Cell Cycle—TP53—bone cancer	1.16e-05	0.000228	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TGFBR2—bone cancer	1.16e-05	0.000227	CbGpPWpGaD
Gefitinib—ABCG2—bone marrow—bone cancer	1.16e-05	0.0105	CbGeAlD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	1.16e-05	0.000227	CbGpPWpGaD
Gefitinib—ABCG2—spinal cord—bone cancer	1.16e-05	0.0104	CbGeAlD
Gefitinib—ALB—Metabolism—NT5C3A—bone cancer	1.15e-05	0.000225	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NDUFA12—bone cancer	1.15e-05	0.000225	CbGpPWpGaD
Gefitinib—MKNK1—Disease—MDM2—bone cancer	1.15e-05	0.000224	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—GNA11—bone cancer	1.14e-05	0.000223	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NDUFA12—bone cancer	1.14e-05	0.000223	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GRM4—bone cancer	1.14e-05	0.000222	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—RGS1—bone cancer	1.14e-05	0.000222	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—KIT—bone cancer	1.13e-05	0.000221	CbGpPWpGaD
Gefitinib—MKNK1—Disease—PTGS2—bone cancer	1.11e-05	0.000216	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—ATF1—bone cancer	1.1e-05	0.000215	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—JUN—bone cancer	1.1e-05	0.000215	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—IGF1R—bone cancer	1.09e-05	0.000214	CbGpPWpGaD
Gefitinib—EGFR—MAPK Signaling Pathway—TP53—bone cancer	1.08e-05	0.000212	CbGpPWpGaD
Gefitinib—IRAK4—Innate Immune System—EGFR—bone cancer	1.08e-05	0.000212	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—GNA11—bone cancer	1.08e-05	0.000211	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—GNA11—bone cancer	1.08e-05	0.00021	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MET—bone cancer	1.08e-05	0.00021	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—CDK4—bone cancer	1.08e-05	0.00021	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IL3—bone cancer	1.08e-05	0.00021	CbGpPWpGaD
Gefitinib—CYP3A4—Biological oxidations—GSTP1—bone cancer	1.07e-05	0.00021	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—BRAF—bone cancer	1.07e-05	0.000208	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—ATF1—bone cancer	1.06e-05	0.000208	CbGpPWpGaD
Gefitinib—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	1.06e-05	0.000207	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—MDM2—bone cancer	1.05e-05	0.000206	CbGpPWpGaD
Gefitinib—EGFR—Disease—ENO2—bone cancer	1.05e-05	0.000205	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—SMO—bone cancer	1.04e-05	0.000203	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IL3—bone cancer	1.04e-05	0.000202	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—NT5C3A—bone cancer	1.04e-05	0.000202	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—KIT—bone cancer	1.02e-05	0.000199	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—NT5C3A—bone cancer	1.01e-05	0.000198	CbGpPWpGaD
Gefitinib—CSNK1E—Cell Cycle—TP53—bone cancer	9.98e-06	0.000195	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GRM1—bone cancer	9.87e-06	0.000193	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—IL3—bone cancer	9.8e-06	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	9.78e-06	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Signaling by GPCR—IL3—bone cancer	9.77e-06	0.000191	CbGpPWpGaD
Gefitinib—EGFR—Disease—DHFR—bone cancer	9.72e-06	0.00019	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—BRAF—bone cancer	9.59e-06	0.000187	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—NT5C3A—bone cancer	9.53e-06	0.000186	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—GNA11—bone cancer	9.52e-06	0.000186	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—NT5C3A—bone cancer	9.45e-06	0.000185	CbGpPWpGaD
Gefitinib—EGFR—Axon guidance—MMP9—bone cancer	9.45e-06	0.000185	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—KIT—bone cancer	9.35e-06	0.000183	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—MDM2—bone cancer	9.24e-06	0.00018	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TGFBR2—bone cancer	9.19e-06	0.00018	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—JUN—bone cancer	9.15e-06	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Immune System—ATF1—bone cancer	9.15e-06	0.000179	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP2—bone cancer	8.97e-06	0.000175	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—KIT—bone cancer	8.94e-06	0.000175	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—MDM2—bone cancer	8.93e-06	0.000174	CbGpPWpGaD
Gefitinib—EGFR—Immune System—IL3—bone cancer	8.92e-06	0.000174	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TGFBR2—bone cancer	8.86e-06	0.000173	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—ATF1—bone cancer	8.85e-06	0.000173	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—IGF1R—bone cancer	8.65e-06	0.000169	CbGpPWpGaD
Gefitinib—ERBB3—Innate Immune System—EGFR—bone cancer	8.64e-06	0.000169	CbGpPWpGaD
Gefitinib—ERBB3—Disease—KIT—bone cancer	8.64e-06	0.000169	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IL3—bone cancer	8.63e-06	0.000169	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.61e-06	0.000168	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—PTGS2—bone cancer	8.61e-06	0.000168	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—KIT—bone cancer	8.59e-06	0.000168	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—IGF1R—bone cancer	8.34e-06	0.000163	CbGpPWpGaD
Gefitinib—ERBB3—Adaptive Immune System—EGFR—bone cancer	8.3e-06	0.000162	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.3e-06	0.000162	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—ENO2—bone cancer	8.19e-06	0.00016	CbGpPWpGaD
Gefitinib—ERBB3—Disease—BRAF—bone cancer	8.12e-06	0.000159	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MDM2—bone cancer	8.04e-06	0.000157	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—JUN—bone cancer	8.03e-06	0.000157	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—KIT—bone cancer	7.94e-06	0.000155	CbGpPWpGaD
Gefitinib—MKNK1—Disease—EGFR—bone cancer	7.84e-06	0.000153	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—KIT—bone cancer	7.79e-06	0.000152	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—DHFR—bone cancer	7.6e-06	0.000148	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NDUFA12—bone cancer	7.52e-06	0.000147	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.48e-06	0.000146	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—BRAF—bone cancer	7.46e-06	0.000146	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TGFBR2—bone cancer	7.38e-06	0.000144	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—MDM2—bone cancer	7.37e-06	0.000144	CbGpPWpGaD
Gefitinib—IRAK1—Innate Immune System—EGFR—bone cancer	7.2e-06	0.000141	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GNA11—bone cancer	7.1e-06	0.000139	CbGpPWpGaD
Gefitinib—EGFR—Disease—TGFBR2—bone cancer	7.05e-06	0.000138	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—MDM2—bone cancer	7.04e-06	0.000138	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—JUN—bone cancer	6.99e-06	0.000136	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—SMO—bone cancer	6.96e-06	0.000136	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—IGF1R—bone cancer	6.94e-06	0.000136	CbGpPWpGaD
Gefitinib—ERBB3—Disease—MDM2—bone cancer	6.8e-06	0.000133	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—MMP9—bone cancer	6.8e-06	0.000133	CbGpPWpGaD
Gefitinib—EGFR—Adaptive Immune System—MDM2—bone cancer	6.76e-06	0.000132	CbGpPWpGaD
Gefitinib—EGFR—Developmental Biology—MMP9—bone cancer	6.74e-06	0.000132	CbGpPWpGaD
Gefitinib—ERBB3—Disease—PTGS2—bone cancer	6.56e-06	0.000128	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—CYP3A4—bone cancer	6.44e-06	0.000126	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—PLAU—bone cancer	6.43e-06	0.000126	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—JUN—bone cancer	6.4e-06	0.000125	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—GNA11—bone cancer	6.36e-06	0.000124	CbGpPWpGaD
Gefitinib—IRAK4—Immune System—EGFR—bone cancer	6.31e-06	0.000123	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—KIT—bone cancer	6.27e-06	0.000123	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MDM2—bone cancer	6.25e-06	0.000122	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—NT5C3A—bone cancer	6.23e-06	0.000122	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—MDM2—bone cancer	6.13e-06	0.00012	CbGpPWpGaD
Gefitinib—EGFR—Innate Immune System—JUN—bone cancer	6.12e-06	0.00012	CbGpPWpGaD
Gefitinib—CSNK1E—Disease—EGFR—bone cancer	6.1e-06	0.000119	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—KIT—bone cancer	6.05e-06	0.000118	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—ATF1—bone cancer	5.92e-06	0.000116	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—BRAF—bone cancer	5.9e-06	0.000115	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.88e-06	0.000115	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—ENO2—bone cancer	5.87e-06	0.000115	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IL3—bone cancer	5.77e-06	0.000113	CbGpPWpGaD
Gefitinib—ABCB1—bone marrow—bone cancer	5.73e-06	0.00517	CbGeAlD
Gefitinib—ABCB1—spinal cord—bone cancer	5.71e-06	0.00515	CbGeAlD
Gefitinib—ERBB3—Signaling Pathways—BRAF—bone cancer	5.68e-06	0.000111	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—ENO2—bone cancer	5.55e-06	0.000108	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—GSTP1—bone cancer	5.51e-06	0.000108	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—EGFR—bone cancer	5.49e-06	0.000107	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—DHFR—bone cancer	5.45e-06	0.000106	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—JUN—bone cancer	5.43e-06	0.000106	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—JUN—bone cancer	5.33e-06	0.000104	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—MMP9—bone cancer	5.29e-06	0.000103	CbGpPWpGaD
Gefitinib—EGFR—Immune System—KIT—bone cancer	5.21e-06	0.000102	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—DHFR—bone cancer	5.15e-06	0.000101	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GNA11—bone cancer	5.09e-06	9.94e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—ENO2—bone cancer	5.06e-06	9.88e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—KIT—bone cancer	5.03e-06	9.83e-05	CbGpPWpGaD
Gefitinib—ERBB3—Immune System—EGFR—bone cancer	5.03e-06	9.83e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MDM2—bone cancer	4.94e-06	9.65e-05	CbGpPWpGaD
Gefitinib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.94e-06	9.65e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TGFBR2—bone cancer	4.93e-06	9.64e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GNA11—bone cancer	4.81e-06	9.39e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—KIT—bone cancer	4.81e-06	9.39e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MDM2—bone cancer	4.76e-06	9.3e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—BRAF—bone cancer	4.73e-06	9.24e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—DHFR—bone cancer	4.69e-06	9.16e-05	CbGpPWpGaD
Gefitinib—ERBB3—Disease—EGFR—bone cancer	4.65e-06	9.08e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—IGF1R—bone cancer	4.64e-06	9.07e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—CYP3A4—bone cancer	4.61e-06	9.01e-05	CbGpPWpGaD
Gefitinib—MKNK1—Signaling Pathways—TP53—bone cancer	4.61e-06	9.01e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—ENO2—bone cancer	4.54e-06	8.87e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—BRAF—bone cancer	4.52e-06	8.83e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—ENO2—bone cancer	4.43e-06	8.65e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GNA11—bone cancer	4.38e-06	8.56e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—CYP3A4—bone cancer	4.36e-06	8.52e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.34e-06	8.47e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—JUN—bone cancer	4.29e-06	8.39e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—EGFR—bone cancer	4.27e-06	8.34e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—DHFR—bone cancer	4.21e-06	8.22e-05	CbGpPWpGaD
Gefitinib—IRAK1—Immune System—EGFR—bone cancer	4.19e-06	8.19e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—MMP9—bone cancer	4.18e-06	8.16e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—ENO2—bone cancer	4.17e-06	8.15e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—JUN—bone cancer	4.14e-06	8.09e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—ENO2—bone cancer	4.14e-06	8.08e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—DHFR—bone cancer	4.11e-06	8.03e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—MDM2—bone cancer	4.1e-06	8.01e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—MMP9—bone cancer	4.03e-06	7.87e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—CYP3A4—bone cancer	3.97e-06	7.76e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MDM2—bone cancer	3.97e-06	7.74e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.95e-06	7.72e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—GSTP1—bone cancer	3.95e-06	7.71e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GNA11—bone cancer	3.94e-06	7.69e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—DHFR—bone cancer	3.87e-06	7.56e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GNA11—bone cancer	3.84e-06	7.5e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—DHFR—bone cancer	3.84e-06	7.5e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—MDM2—bone cancer	3.79e-06	7.4e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—GSTP1—bone cancer	3.73e-06	7.28e-05	CbGpPWpGaD
Gefitinib—EGFR—Disease—PTGS2—bone cancer	3.65e-06	7.13e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GNA11—bone cancer	3.62e-06	7.07e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GNA11—bone cancer	3.59e-06	7.01e-05	CbGpPWpGaD
Gefitinib—CSNK1E—Signaling Pathways—TP53—bone cancer	3.59e-06	7.01e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—CYP3A4—bone cancer	3.57e-06	6.97e-05	CbGpPWpGaD
Gefitinib—EGFR—Immune System—JUN—bone cancer	3.56e-06	6.96e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.55e-06	6.93e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—CYP3A4—bone cancer	3.48e-06	6.8e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—JUN—bone cancer	3.45e-06	6.73e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—GSTP1—bone cancer	3.4e-06	6.64e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—EGFR—bone cancer	3.38e-06	6.6e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—KIT—bone cancer	3.37e-06	6.58e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—MMP9—bone cancer	3.35e-06	6.55e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—CYP3A4—bone cancer	3.28e-06	6.41e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—EGFR—bone cancer	3.25e-06	6.36e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—CYP3A4—bone cancer	3.25e-06	6.35e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	3.24e-06	6.32e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—BRAF—bone cancer	3.16e-06	6.18e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—GSTP1—bone cancer	3.05e-06	5.96e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—GSTP1—bone cancer	2.98e-06	5.82e-05	CbGpPWpGaD
Gefitinib—ABCG2—Metabolism—PTGS2—bone cancer	2.85e-06	5.57e-05	CbGpPWpGaD
Gefitinib—MAP2K5—Signaling Pathways—TP53—bone cancer	2.84e-06	5.54e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—GSTP1—bone cancer	2.81e-06	5.48e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—GSTP1—bone cancer	2.78e-06	5.43e-05	CbGpPWpGaD
Gefitinib—ERBB3—Signaling Pathways—TP53—bone cancer	2.73e-06	5.34e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—ENO2—bone cancer	2.73e-06	5.33e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—EGFR—bone cancer	2.71e-06	5.29e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MDM2—bone cancer	2.65e-06	5.18e-05	CbGpPWpGaD
Gefitinib—ALB—Hemostasis—TP53—bone cancer	2.59e-06	5.05e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—DHFR—bone cancer	2.53e-06	4.95e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GNA11—bone cancer	2.37e-06	4.62e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—JUN—bone cancer	2.3e-06	4.5e-05	CbGpPWpGaD
Gefitinib—IRAK1—Signaling Pathways—TP53—bone cancer	2.28e-06	4.44e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—MMP9—bone cancer	2.24e-06	4.38e-05	CbGpPWpGaD
Gefitinib—CYP3A5—Metabolism—PTGS2—bone cancer	2.04e-06	3.99e-05	CbGpPWpGaD
Gefitinib—CYP1A1—Metabolism—PTGS2—bone cancer	1.93e-06	3.77e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—GSTP1—bone cancer	1.83e-06	3.58e-05	CbGpPWpGaD
Gefitinib—ALB—Metabolism—PTGS2—bone cancer	1.76e-06	3.44e-05	CbGpPWpGaD
Gefitinib—CYP2C19—Metabolism—PTGS2—bone cancer	1.58e-06	3.09e-05	CbGpPWpGaD
Gefitinib—ABCB1—Metabolism—PTGS2—bone cancer	1.54e-06	3.01e-05	CbGpPWpGaD
Gefitinib—EGFR—Signaling Pathways—TP53—bone cancer	1.52e-06	2.97e-05	CbGpPWpGaD
Gefitinib—CYP2D6—Metabolism—PTGS2—bone cancer	1.45e-06	2.84e-05	CbGpPWpGaD
Gefitinib—CYP2C9—Metabolism—PTGS2—bone cancer	1.44e-06	2.82e-05	CbGpPWpGaD
Gefitinib—CYP3A4—Metabolism—PTGS2—bone cancer	9.51e-07	1.86e-05	CbGpPWpGaD
